



MOREPEN



Date: 07/11/2020

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

Symbol: MOREPENLAB

Scrip Code: 500288

Subject: Intimation of Post Results (Q2 - FY 2020-2021) Conference Call

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that subsequent to the declaration of unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2020, the Company is organizing an 'Investors and Analyst Conference Call' on **Tuesday, 10th November, 2020 at 12.00 Noon (IST)**.


The details of the conference call are attached herewith.

This is for your information and records.

Thanking you.

Yours faithfully,

For Morepen Laboratories Limited


(Vipul Kumar Srivastava)
Company Secretary

Encl.: As Above

Morepen Laboratories Limited

Corp. Off.: 4th Floor, Antriksh Bhawan, 22 K.G.Marg, New Delhi- 110 001, INDIA
Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: www.morepen.com
CIN NO. L24231 HP1984PLC006028

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205
Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com



Morepen Laboratories Limited is one of India’s leading API & Health Care diagnostics manufacturer. The company will be hosting a conference call for investors and analyst community on **Tuesday, November 10, 2020 at 12.00 Noon IST** for Q2 & H1; FY21 results.

The call will be initiated with a brief management discussion on the company, business segments and earnings performance followed by an interactive question and answer session.

On behalf of the company the call will addressed by:

- **Mr. Sushil Suri : Chairman and Managing Director**
- **Mr. Ajay Sharma : Chief Financial Officer**

Details of the conference call are as follows:

Tuesday, 10th November 2020 – 12.00 Noon IST

Conference Dial-in numbers	
Mumbai (Primary no.)	+91 22- 62801239
Universal access	022- 7115 8140
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448

Note: When using dial-in numbers mentioned above please do so 10 minutes prior to the conference scheduled to ensure that you are connected to your call in time.

=====

About Morepen Laboratories Ltd.

Morepen Laboratories Ltd. is a 36-year old, around Rs. 900 Cr. pharmaceutical and healthcare products company. The company went public in the year 1993 and is currently listed at both the Bombay Stock Exchange as well as the National Stock Exchange.

Morepen is engaged in the manufacturing and sale of APIs/ Bulk Drugs, Home Diagnostics, Formulations and OTC products. The company’s state-of-the-art manufacturing facility at Baddi (Himachal Pradesh) comprises a scientifically integrated complex of 10 plants, each with a specific product profile. The USFDA approved plant at Masulkhana is for manufacture of

Loratadine, an anti-allergy drug – internationally known as Claritin. Desloratadine and the new blockbuster drug Montelukast are also manufactured at this FDA approved site.

The large and spread out manufacturing facility at Baddi has EU GMP & WHO GMP Standards and manufactures latest and much in demand APIs like Atorvastatin, Rosuvastatin, Fexofenadine and others for regulated markets of Europe, USA and also for non-regulated markets across the globe.

Morepen markets over 100 branded formulations under six major therapeutic segments in the domestic market. The company's manufacturing facilities are backed by a strong dedicated team of research and development (R&D) professionals who ensure stringent quality standards. In Home - Diagnostics business, Morepen has a formidable presence in Blood Glucose Monitors and Blood Pressure Monitors, in the domestic markets. The company's OTC brands are being promoted under its wholly owned subsidiary Dr. Morepen Limited. Dr. Morepen's famous OTC product line, including Burnol, Lemolate, Sat-Isabgol, Pain-X and others, has a significant presence in the domestic market.

For any further information please contact

Mr. Sunil Mudgal
Kirin Advisors
Ph -9820975849
Email: sunil@kirinadvisors.com

DISCLAIMER:

Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and abroad. Actual results might differ substantially from those expressed or implied. Morepen Laboratories Ltd. and its Management will not be in any way responsible for any action taken based on such statements and discussions. Morepen also undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.